Article Information
History
- January 1, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- George R. Abraham, BA BMBCh MRCPa,b,*,
- Rhoda E. Kuc, GIBiolb,
- Magnus Althage, PhDc,
- Peter J. Greasley, PhDc,
- Philip Ambery, FRCPc,
- Janet J. Maguire, PhDb,
- Ian B. Wilkinson, MA, DM, FRCPb,
- Stephen P. Hoole, MA, BM, BCh, DM, FRCPa,
- Joseph Cheriyan, MBChB MA, FRCPb,d,§ and
- Anthony P. Davenport, ScDb,§
- aRoyal Papworth Hospital NHS Foundation Trust, Cambridge Biomedical Campus Cambridge, U.K.
- bDivision of Experimental Medicine and Immunotherapeutics, University of Cambridge, Addenbrooke’s Hospital, Cambridge U.K.
- cLate-stage Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
- dClinical Pharmacology Department and Cardiovascular Office, Cambridge Clinical Trials Unit, Cambridge University Hospitals NHS Foundation Trust, UK
- ↵*Address for correspondence: George R. Abraham, Cardiology Research Fellow, Royal Papworth Hospital NHS Foundation Trust, Papworth Road, Cambridge Biomedical Campus, CB2 0AY. Email: George.abraham{at}nhs.net
Posted January 01, 2022.
